DIRECTOR OF INNOVATION AND BUSINESS DEVELOPMENT, PROCOS SPA
"We are currently building a new workshop in which we are specifically going to add small-scale lines to support clinical trial supply and generic product manufacturing."
"We believe that a company’s worth is not just in its financial achievements but also in its contributions to ethical practices and sustainable development."
"We used our voice to educate on the value of medical innovation and boasted the strength of New Jersey’s vibrant ecosystem, which was responsible for more than 50% of all novel FDA approvals in 2023."
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.